Comprehensive Program for Hereditary Transthyretin Amyloidosis

Not yet recruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

November 1, 2028

Study Completion Date

December 1, 2028

Conditions
Amyloidosis in Transthyretin (TTR)Amyloidosis, Familial
Interventions
OTHER

clinical assessments and complementary examinations

"Evaluation Plan~Comprehensive Examination: Complete medical history and physical examination of all body systems, including height and weight measurements.~Clinical Parameters: Pulse/heart rate, respiratory rate, and SpO2 will be monitored. The NYHA classification will be used to assess heart failure if applicable.~Neurological Examination: Includes motor strength testing, sensory testing (pinprick, light touch, temperature, proprioception), deep tendon reflexes, and gait assessment.~Electrocardiogram (ECG): A 12-lead ECG will be performed with the subject at rest for at least 5 minutes in a supine position.~24-hour Holter Monitoring: Conducted in cases of suspected arrhythmias or echocardiographic findings indicating arrhythmias.~Color Dosments and complementary examinations"

Trial Locations (1)

1814

Hospital Cuenca Alta de Cañuelas, Cañuelas

All Listed Sponsors
lead

Hospital de Alta Complejidad en Red

OTHER

NCT07213297 - Comprehensive Program for Hereditary Transthyretin Amyloidosis | Biotech Hunter | Biotech Hunter